Skip to content

Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships

Home
Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships
Contact

C

1 min read

[Newsletter-5] NEWS/INFOS

Author Bertrand Fabien
Published 31 mai 2020

May 29, 2020.

>> Official news bulletin for XAV19/Bulletin officiel du XAV19 <<

Download our newsletter (english version)
Télécharger notre newsletter (version française)

Related Posts

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

Corporate
Technology
Pipeline

Clinical trials
Newsroom
Partnerships

Contact
Legal notice

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr